Glossary: AFP: Alpha-fetoprotein; aHR: Adjusted hazard ratio; ALT: Alanine aminotransferase; cccDNA: Close covalent circular deoxyribonucleic acid; CHB: Chronic hepatitis B; cHR: Crude hazard ratio; CI: Confidence interval; FIB-4: Fibrosis-4 index; HBsAg: Hepatitis B surface antigen; HBV: Hepatiti

Glossary: AE: Adverse event; ALT: Alanine aminotransferase; CHB: Chronic hepatitis B; HBeAg: Hepatitis B e-antigen; HBsAg: Hepatitis B surface antigen; HBV: Heaptitis B virus; DNA: Deoxyribonucleic acid; QD: Once a day; TAF: Tenofovir alafenamide; TDF: Tenofovir disoproxil fumarate; WHO: World Hea

Glossary: AASLD: American Association for the Study of Liver Diseases; ALT: Alanine aminotransferase; BMD: Bone mineral density; CHB: Chronic hepatitis B; CLCr: Creatinine clearance; HBeAg: Hepatitis B e-antigen; HBV: Hepatitis B virus; DNA: Deoxyribonucleic acid; PBO: Placebo; QD: Once a day; sCr

Glossary: AASLD: American Associatioin fo the Study of Liver Diseases; ALT: Alanine aminotransferase; CHB: Chronic hepatitis B; DNA: Deoxyribonucleic acid; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; PS: Propensity score; sCr:

Glossary: aRR: Adjusted rate ratio; CI: Confidence interval; HCC: Hematocellular carcinoma; HCV: Hepatitis C virus

Glossary: ALT: Alanine aminotransferase; aOR: Adjusted odd ratio; BMD: Bone mineral density; CHB: Chronic hepatitis B; CI: Confidence interval; CKD: Chronic kidney disease; CR: Complete response; DNA: Deoxyribonucleic acid; eGFR: Estimated glomerular filtration rate; ETV: Entecavir; HBV: Hepatitis

In a multicenter, retrospective cohort study, switching from other nucleos(t)ide analogues (NAs) to tenofovir alafenamide (TAF) was found to be effective in improving outcomes among patients with chronic hepatitis B (CHB) and safe for up to 3 years.¹ This study added substantially to the evidence of efficacy and safety of TAF in the real-world setting, supporting its wider adoption in light of the rapidly aging CHB population and increasing the prevalence of aging-related comorbidities.¹

Preservation of patients' renal function can be crucial in the management of CHB. Some patients such as those with cardiovascular diseases, despite having a prevailing eGFR. are more likely to have their renal function declined in the long term. Also. cancer patients frequently encounter infections that may lead to kIdney injury through sepsis or use come nephrotoxic antibiotics, such as aminoglycoside. Tenotovir alafenamide (TAF). a novel option with the benefits of preserving patients . is a major advance in the treatment landscape of CHB in recent years and can be the preferred therapy for CHB patients for the renal benefits.